| Metric | Value (₹ Cr) | Q1 FY26 | Q2 FY25 |
|---|---|---|---|
| Revenue | 18.50 | 3.4% | 2.0% |
| Total Income | 18.66 | 4.1% | 0.8% |
| Expenditure | 13.47 | 13.8% | 13.7% |
| PBT | 5.19 | 125.7% | 78.0% |
| Net Profit | 4.64 | 168.0% | 102.0% |
| OPM | 28.36% | 13.56pp | 16.22pp |
| NPM | 24.86% | 15.21pp | 12.46pp |
| EPS | 3.78 | 158.9% | 92.9% |
Sanjivani Paranteral Ltd Reports Strong Performance in Q2 FY26 Despite Challenges, Revenue Down 14.5% YoY
15 Nov 2025 · 15 Nov 2025, 10:36 pm
Summary
Sanjivani Paranteral Ltd, a pharmaceutical company based in Mumbai, reported a strong performance for the quarter ended 30th September 2025. Despite a 14.5% YoY decline in revenue to Rs. 155.0 mn, the company's EBITDA margin stood at 15.5%. The injectables segment reported strong growth, while the oral segment was impacted by shipment related challenges. The company is actively investing in R&D to expand its product portfolio and remains committed to its long-term strategy.
Key Highlights
- 1
Revenue from operations declined by 14.5% YoY to Rs. 155.0 mn
- 2
EBITDA margin stood at 15.5%
- 3
Profit After Tax (PAT) stood at Rs. 16.4 mn (down 28.6% YoY)
- 4
Injectables segment reported strong growth
- 5
Oral segment was impacted by shipment related challenges
- 6
Company is investing in R&D to expand product portfolio
- 7
Export markets contributed significantly to overall revenue
Management Comments
Mr. Ashwani Khemka
We are pleased to report a steady performance for Q1FY26, in the backdrop of challenges and uncertainties in the global trade environment. While the injectables segment reported strong growth, oral segment was impacted by shipment related challenges due to macro uncertainties. This will improve as we look into the coming quarters. Our commitment to long-term strategy remains unwavering. We are actively investing in R&D to expand our product portfolio. The continued performance of our export markets, which contributed significantly to our overall revenue, is a testament to this strategy. Despite the challenges posed by a dynamic global environment, our diversified portfolio and strategic focus should help us achieve significant revenue growth going ahead.
Informational and educational content only. Not investment advice.